Tag: FGFR3

Derazantinib Shows Clinical Benefit, Manageable Safety Profile in Patients With Cholangiocarcinoma

Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma. Treatment with derazantinib, an FGFR inhibitor, produced a meaningful clinical benefit with a manageable safety profile in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA), according to data from…

Continue Reading Derazantinib Shows Clinical Benefit, Manageable Safety Profile in Patients With Cholangiocarcinoma

Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential

Weisman, D. & McKeith, I. Dementia with Lewy Bodies. Semin. Neurol. 27, 042–047 (2007). Article  Google Scholar  Foguem, C. & Manckoundia, P. Lewy Body Disease: Clinical and Pathological “Overlap Syndrome” Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr. Neurol. Neurosci. Rep. 2018 18:5 18, 1–9 (2018). CAS  Google Scholar …

Continue Reading Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential

Pemigatinib Improves OS in FGFR2-Altered Cholangiocarcinoma

A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement. Pemigatinib (Pemazyre) showed a strong survival benefit in patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement, according to final…

Continue Reading Pemigatinib Improves OS in FGFR2-Altered Cholangiocarcinoma

Dosing of KIN-3248 Begins in Advanced Solid Tumors With FGFR2 and/or FGFR3 Alterations

The first patient has been dosed in the phase 1 KN-4802 trial (NCT05242822) examining the safety, tolerability, and preliminary efficacy of KIN-3248, a next-generation pan-FGFR inhibitor, in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations, according to a press release from Kinnate Biopharma Inc.1 KIN-3248 is an…

Continue Reading Dosing of KIN-3248 Begins in Advanced Solid Tumors With FGFR2 and/or FGFR3 Alterations

First Patient Treated in Study to Determine Tolerability, Dosing of Investigational Drug in Certain Solid Tumors

The first patient has received a dose of a novel drug candidate in an early-phase trial investigating the preliminary tolerability and proper dosage of the treatment in a group of patients with advanced solid tumors that harbor the FGFR2 and/or FGFR3 gene alterations, according to a press release. “With the…

Continue Reading First Patient Treated in Study to Determine Tolerability, Dosing of Investigational Drug in Certain Solid Tumors

Your Source Of Daily World News Crypto Business Technology & Sports News

Cholangiocarcinoma, or bile duct most cancers, is lethal even when caught early. The 5-year survival rate amongst these identified early is 17% to 25%; for many sufferers, the speed is under 10%. Experts say the important thing to bettering these dismal statistics is to give attention to the various genetic…

Continue Reading Your Source Of Daily World News Crypto Business Technology & Sports News

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

Lugano, Switzerland and Palo Alto, CA – Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, announced an…

Continue Reading Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

Erdafitinib Yields Durable Responses in Advanced Urothelial Carcinoma

Erdafitinib demonstrated durable activity in patients with locally advanced or metastatic urothelial carcinoma with specific FGFR alterations, according to updated results from the BLC2001 trial published in The Lancet Oncology.1 The phase 2 BLC2001 trial (ClinicalTrials.gov Identifier: NCT02365597) was designed to investigate erdafitinib in patients with locally advanced and unresectable…

Continue Reading Erdafitinib Yields Durable Responses in Advanced Urothelial Carcinoma

FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells

Stem cell-based therapies offer significant potential for treating disease or injury through the regeneration of damaged tissues. Among the various stem cells available, mesenchymal stem cells (MSCs) are garnering considerable interest because of their availability, ease of isolation, and multipotency. Importantly, under appropriate culture conditions, MSCs can be selectively induced…

Continue Reading FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Dual Targeting of CDKN2A and PIK3CA May Offer Better Outcomes in Urothelial Carcinoma

Genomic testing varies in the academic and community setting. For community settings, commercial panels are available. However, academic settings have access to tools that provide a more comprehensive views of the genome. Investigators used patient-derived UC organoid (PDO) harboring FGFR3, PIK3CA, and CDKN2A mutations. Dose-response curves of alpelisib (Piqray), abemaciclib…

Continue Reading Dual Targeting of CDKN2A and PIK3CA May Offer Better Outcomes in Urothelial Carcinoma